Theodoros Kelesidis1, Thuy Tien T Tran2, James H Stein3, Todd T Brown4, Carlee Moser2, Heather J Ribaudo2, Michael P Dube5, Robert Murphy6, Otto O Yang1, Judith S Currier1, Grace A McComsey7. 1. David Geffen School of Medicine at the University of California, Los Angeles. 2. Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 3. University of Wisconsin School of Medicine and Public Health, Madison. 4. Johns Hopkins University, Baltimore, Maryland. 5. Keck School of Medicine at the University of Southern California, Los Angeles. 6. Northwestern University, Evanston, Illinois. 7. Case Western Reserve University School of Medicine, Cleveland, Ohio University Hospitals Case Medical Center, Cleveland, Ohio.
Abstract
BACKGROUND: It is unclear whether the integrase inhibitor raltegravir (RAL) reduces inflammation and immune activation compared with ritonavir-boosted protease inhibitors (PIs). METHODS: In a prospective, randomized, multicenter clinical trial that included 328 human immunodeficiency type 1 (HIV-1)-infected, treatment-naive participants were randomized to receive tenofovir disoproxil fumarate-emtricitabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r), or RAL. A total of 234 participants (71%) with HIV-1 RNA levels <50 copies/mL by week 24 were included. Plasma biomarkers of inflammation and coagulation that were analysed included high-sensitivity C-reactive protein, interleukin-6 (IL-6), GlycA, D-dimer, soluble CD14 (sCD14), sCD163, and sIL-2r; blood cellular markers included %CD38+DR+ of T-cell subsets and %CD14+CD16+ and%CD14(dim)CD16+ monocyte subsets. Changes from baseline were examined at earlier (24 or 48 weeks) and later (96 weeks) time points, with 95% confidence intervals on fold-change. Pairwise treatment groups were compared using Wilcoxon rank sum tests, with P values adjusted for false discovery rate control. RESULTS: Changes in biomarkers varied by regimen during the 96 weeks of follow-up as follows: hsCRP declined with ATV/r and RAL, IL-6 declined only with RAL, and GLycA decreased in all groups. D-dimer declined with ATV/r and DRV/r and was unchanged with RAL. Markers of T-cell activation and sCD163 (but not sCD14 and CD14-+CD16+) declined in all groups. CONCLUSIONS: Despite some differences in specific markers of inflammation and immune activation between the antiretroviral therapy (ART) regimens, we found no consistent evidence that the reduction of inflammation and immune activation with ART initiation was different between RAL and PI-based regimens. CLINICAL TRIALS REGISTRATION: NCT00811954 and NCT00851799.
RCT Entities:
BACKGROUND: It is unclear whether the integrase inhibitor raltegravir (RAL) reduces inflammation and immune activation compared with ritonavir-boosted protease inhibitors (PIs). METHODS: In a prospective, randomized, multicenter clinical trial that included 328 humanimmunodeficiency type 1 (HIV-1)-infected, treatment-naive participants were randomized to receive tenofovir disoproxil fumarate-emtricitabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r), or RAL. A total of 234 participants (71%) with HIV-1 RNA levels <50 copies/mL by week 24 were included. Plasma biomarkers of inflammation and coagulation that were analysed included high-sensitivity C-reactive protein, interleukin-6 (IL-6), GlycA, D-dimer, soluble CD14 (sCD14), sCD163, and sIL-2r; blood cellular markers included %CD38+DR+ of T-cell subsets and %CD14+CD16+ and%CD14(dim)CD16+ monocyte subsets. Changes from baseline were examined at earlier (24 or 48 weeks) and later (96 weeks) time points, with 95% confidence intervals on fold-change. Pairwise treatment groups were compared using Wilcoxon rank sum tests, with P values adjusted for false discovery rate control. RESULTS: Changes in biomarkers varied by regimen during the 96 weeks of follow-up as follows: hsCRP declined with ATV/r and RAL, IL-6 declined only with RAL, and GLycA decreased in all groups. D-dimer declined with ATV/r and DRV/r and was unchanged with RAL. Markers of T-cell activation and sCD163 (but not sCD14 and CD14-+CD16+) declined in all groups. CONCLUSIONS: Despite some differences in specific markers of inflammation and immune activation between the antiretroviral therapy (ART) regimens, we found no consistent evidence that the reduction of inflammation and immune activation with ART initiation was different between RAL and PI-based regimens. CLINICAL TRIALS REGISTRATION: NCT00811954 and NCT00851799.
Authors: Jacqueline Neuhaus; David R Jacobs; Jason V Baker; Alexandra Calmy; Daniel Duprez; Alberto La Rosa; Lewis H Kuller; Sarah L Pett; Matti Ristola; Michael J Ross; Michael G Shlipak; Russell Tracy; James D Neaton Journal: J Infect Dis Date: 2010-06-15 Impact factor: 5.226
Authors: J E Lake; G A McComsey; T Hulgan; C A Wanke; A Mangili; S L Walmsley; S A Stramotas; R Tracy; J S Currier Journal: HIV Med Date: 2014-02-10 Impact factor: 3.180
Authors: Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek Journal: J Infect Dis Date: 2011-01-20 Impact factor: 5.226
Authors: Maria J Buzón; Marta Massanella; Josep M Llibre; Anna Esteve; Viktor Dahl; Maria C Puertas; Josep M Gatell; Pere Domingo; Roger Paredes; Mark Sharkey; Sarah Palmer; Mario Stevenson; Bonaventura Clotet; Julià Blanco; Javier Martinez-Picado Journal: Nat Med Date: 2010-03-14 Impact factor: 53.440
Authors: Kristine B Patterson; Heather A Prince; Trenton Stevens; Nicholas J Shaheen; Evan S Dellon; Ryan D Madanick; Steven Jennings; Myron S Cohen; Angela D M Kashuba Journal: AIDS Date: 2013-06-01 Impact factor: 4.177
Authors: Hiroyu Hatano; Matthew C Strain; Rebecca Scherzer; Peter Bacchetti; Deborah Wentworth; Rebecca Hoh; Jeffrey N Martin; Joseph M McCune; James D Neaton; Russell P Tracy; Priscilla Y Hsue; Douglas D Richman; Steven G Deeks Journal: J Infect Dis Date: 2013-08-23 Impact factor: 5.226
Authors: Jason V Baker; Jacqueline Neuhaus; Daniel Duprez; Lewis H Kuller; Russell Tracy; Waldo H Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Daniel E Nixon; Nicholas I Paton; James D Neaton Journal: J Acquir Immune Defic Syndr Date: 2011-01-01 Impact factor: 3.731
Authors: Theodoros Kelesidis; Carlee Moser; James H Stein; Todd T Brown; Thuy Tien T Tran; Heather J Ribaudo; Michael P Dube; Otto O Yang; Judith S Currier; Grace A McComsey Journal: J Infect Dis Date: 2016-06-28 Impact factor: 5.226
Authors: Sarah F Benki-Nugent; Ira Martopullo; Tony Laboso; Nancy Tamasha; Dalton C Wamalwa; Kenneth Tapia; Agnes Langat; Elizabeth Maleche-Obimbo; Christina M Marra; Paul Bangirana; Michael J Boivin; Grace C John-Stewart Journal: J Acquir Immune Defic Syndr Date: 2019-05-01 Impact factor: 3.731
Authors: Michael L Freeman; Carey L Shive; Thao P Nguyen; Souheil-Antoine Younes; Soumya Panigrahi; Michael M Lederman Journal: J Infect Dis Date: 2016-10-01 Impact factor: 5.226